Control of the disease (It will to evaluate according to the International response criteria for each chronic B-cell lymphoproliferative syndrome (CLPS) in the categories "Control of the disease" (complete + partial response + stable disease) and "Non-responders" (death + progressive disease) . Measurement time: weeks 13, 29, 41 and 52.
Relapse-Free Survival (The time from the date of achievement of a complete response until the date of relapse or death from any cause. Defined only for patients achieving complete response). Measuring time: 52 weeks
Event-free survival (The time from treatment began until treatment failure, or relapse or death from any cause). Measurement time: 52 weeks
Progression free survival (The time from the start of treatment until to the date of disease progression or death from any cause) Measurement time: 29 and 52 weeks
Survival rates (Percentage of patients alive from the diagnosis and the start of treatment). Measuring time: week 29 and week 52
Time to progression (Time measured from the start of treatment to the date of disease progression). Measurement time: 52 weeks
Time to treatment failure (Time from the start of treatment to the interruption of treatment for any reason, including disease progression, toxicity or death). Measurement time: 52 weeks
Immunogenicity
HAHA response (Yes, No. It will be "Yes" when the value of the density of the patient serum is greater than 2 standard deviations of the value of the sera of healthy donor). Measurement time: At baseline, prior to each administration of product, week 29 and week 52.
Pharmacokinetics
Bioavailability of mAb 14F7hT (numerical value). Measurement time: 1st and 5th administration
Volume of distribution of the MAb 14F7hT (numerical value). Measurement time: 1st and 5th administration
Constant of elimination of the AcM 14F7hT (numerical value). Measurement time: 1st and 5th administration
Maximum concentration of mAb 14F7hT (numerical value). Measurement time: 1st and 5th administration
Average life time of the mAb 14F7hT (numerical value). Measurement time: 1st and 5th administration
Plasma clearance of mAb 14F7hT (numerical value). Measurement time: 1st and 5th administration
Others
Expression of surface markers specific to B cells (Percent of expression of markers). Measurement time: at baseline, week13 and week 29
Expression of ganglioside NGGM3 (Negative, weak staining, moderate staining or intense staining). Measurement time: At baseline and, week 29
Safety
Adverse Events-AE (Occurrence of any AE (Yes, No), Description (name of AE), duration (Time from the event start until its termination), intensity (Mild, Moderate, Severe, AE that threatens or incapacitates and AE that produces death according to the Common Toxicity Criteria-CTCAE version 4.0 of the National Cancer Institute of the United States), Seriousness (Serious or Not applicable (NA) when the AE is not serious), result (recovered, improved, persists, sequelae), attitude towards treatment (no changes, dose modification, temporary or definitive interruption of treatment under study), causality relationship (Definitive, Very Likely, Probable, Possible, Not related, Unknown), Product Batch (number of the batch used)). Measurement time: In each administration of the product and up to 30 days after the last dose of the product is administered
Results of laboratory tests (hematology, blood chemistry and urine). Measurement time: At baseline, weeks 13, 29, 41 and 52.
Vital signs (Blood pressure in mmHg, Heart rate in minutes, Temperature in Celsius degrees). In each product administration.
Result of the physical examination (It will be evaluated by systems, in Normal or Abnormal, depending on the findings, the category not examined will be used, in case it is not done). Measurement time: At baseline, in each administration of the product and in week 52.